Talmapimod (SCIO-469) is an orally active and selective inhibitor of p38alpha MAPK with an IC50 of 9 nM. Talmapimod inhibits the secretion of inflammatory factors (such as TNFalpha, IL-1beta, IL-6, and VEGF) by suppressing the p38alpha MAPK pathway, and it also inhibits angiogenesis and osteoclast activation. Talmapimod inhibits the growth of multiple myeloma cells and induces apoptosis. Talmapimod can be used to study various hematological malignancies (such as multiple myeloma, myelodysplastic syndrome)[1][2][3][4].
